FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2494173637> ?p ?o ?g. }

• W2494173637 endingPage "336" @default.
• W2494173637 startingPage "329" @default.
• W2494173637 abstract "Background Despite the comparable clinical benefit of XELOX (capecitabine with oxaliplatin) and FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), the value of XELOX treatment in combination with cetuximab for metastatic colorectal cancer (mCRC) remains largely unknown. Patients and Methods In this clinical trial we evaluated the efficacy and safety of weekly/biweekly cetuximab administration combined with biweekly XELOX in patients with previously untreated v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type mCRC. The primary end point was response rate (RR) with confirmation, and the secondary end points included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), dose intensity, and the safety of the protocol treatment. Results Forty patients who fulfilled the inclusion criteria participated in this study. The median treatment cycle number was 8 and the median dose intensities were 218 mg/m2/wk for cetuximab, 34 mg/m2/wk for oxaliplatin, and 821 mg/m2/d for capecitabine. One patient showed complete response and partial response was observed in 19 patients, giving an overall RR of 50% (95% confidence interval [CI], 33.8%-66.2%). Stable disease was obtained in 13 patients, resulting in a DCR of 82.5% (95% CI, 67.2%-92.7%). The PFS was 6.5 months (95% CI, 3.5-9.6 months), and the OS was 24.3 months (95% CI, 14.9-33.7 months). The safety profile revealed the common Grade 3/4 adverse events to be acneiform eruption (12.5%), peripheral neuropathy (7.5%), and elevated alanine transaminase levels (7.5%). Grade 3/4 thrombocytopenia and neutropenia occurred only in 5.0% and 2.5% of the patients, respectively. Grade 1 hand-foot syndrome (HFS) was not uncommon (20%), whereas Grade 2/3 HFS occurred in only 3 patients (7.5%). No deaths were reported within 30 days of the last dose. Conclusion Cetuximab with XELOX showed a confirmed overall RR of 50%, which was within the previously reported range of RR. The safety profile showed an acceptable rate and severity of adverse events. In light of the several advantages of XELOX, including convenience and the reported cost-saving aspects, further study of this combination therapy is warranted." @default.
• W2494173637 created "2016-08-23" @default.
• W2494173637 creator A5013344739 @default.
• W2494173637 creator A5023660115 @default.
• W2494173637 creator A5025670670 @default.
• W2494173637 creator A5052173467 @default.
• W2494173637 creator A5058441704 @default.
• W2494173637 creator A5063814775 @default.
• W2494173637 creator A5070859075 @default.
• W2494173637 creator A5084398419 @default.
• W2494173637 creator A5086205123 @default.
• W2494173637 creator A5090027460 @default.
• W2494173637 date "2016-12-01" @default.
• W2494173637 modified "2023-10-16" @default.
• W2494173637 title "A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)" @default.
• W2494173637 cites W1546405854 @default.
• W2494173637 cites W1591638652 @default.
• W2494173637 cites W1956470784 @default.
• W2494173637 cites W1976111194 @default.
• W2494173637 cites W1977648723 @default.
• W2494173637 cites W1984575450 @default.
• W2494173637 cites W1985730089 @default.
• W2494173637 cites W2006022204 @default.
• W2494173637 cites W2019607817 @default.
• W2494173637 cites W2027176779 @default.
• W2494173637 cites W2028486975 @default.
• W2494173637 cites W2034745390 @default.
• W2494173637 cites W2069813673 @default.
• W2494173637 cites W2078602902 @default.
• W2494173637 cites W2084954217 @default.
• W2494173637 cites W2093252674 @default.
• W2494173637 cites W2094634425 @default.
• W2494173637 cites W2102875051 @default.
• W2494173637 cites W2103789431 @default.
• W2494173637 cites W2110097275 @default.
• W2494173637 cites W2121313610 @default.
• W2494173637 cites W2123135306 @default.
• W2494173637 cites W2124410855 @default.
• W2494173637 cites W2135952026 @default.
• W2494173637 cites W2145070131 @default.
• W2494173637 cites W2151329905 @default.
• W2494173637 cites W2154662994 @default.
• W2494173637 cites W2164523473 @default.
• W2494173637 cites W2166400927 @default.
• W2494173637 cites W2171259849 @default.
• W2494173637 cites W2203602330 @default.
• W2494173637 cites W2224006737 @default.
• W2494173637 cites W2409420104 @default.
• W2494173637 cites W4385789423 @default.
• W2494173637 doi "https://doi.org/10.1016/j.clcc.2016.07.003" @default.
• W2494173637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27507128" @default.
• W2494173637 hasPublicationYear "2016" @default.
• W2494173637 type Work @default.
• W2494173637 sameAs 2494173637 @default.
• W2494173637 citedByCount "15" @default.
• W2494173637 countsByYear W24941736372017 @default.
• W2494173637 countsByYear W24941736372018 @default.
• W2494173637 countsByYear W24941736372019 @default.
• W2494173637 countsByYear W24941736372020 @default.
• W2494173637 countsByYear W24941736372021 @default.
• W2494173637 countsByYear W24941736372022 @default.
• W2494173637 crossrefType "journal-article" @default.
• W2494173637 hasAuthorship W2494173637A5013344739 @default.
• W2494173637 hasAuthorship W2494173637A5023660115 @default.
• W2494173637 hasAuthorship W2494173637A5025670670 @default.
• W2494173637 hasAuthorship W2494173637A5052173467 @default.
• W2494173637 hasAuthorship W2494173637A5058441704 @default.
• W2494173637 hasAuthorship W2494173637A5063814775 @default.
• W2494173637 hasAuthorship W2494173637A5070859075 @default.
• W2494173637 hasAuthorship W2494173637A5084398419 @default.
• W2494173637 hasAuthorship W2494173637A5086205123 @default.
• W2494173637 hasAuthorship W2494173637A5090027460 @default.
• W2494173637 hasConcept C121608353 @default.
• W2494173637 hasConcept C126322002 @default.
• W2494173637 hasConcept C143998085 @default.
• W2494173637 hasConcept C197934379 @default.
• W2494173637 hasConcept C203092338 @default.
• W2494173637 hasConcept C2777909004 @default.
• W2494173637 hasConcept C2778260052 @default.
• W2494173637 hasConcept C2779998722 @default.
• W2494173637 hasConcept C2780456651 @default.
• W2494173637 hasConcept C2780962732 @default.
• W2494173637 hasConcept C2781187634 @default.
• W2494173637 hasConcept C526805850 @default.
• W2494173637 hasConcept C535046627 @default.
• W2494173637 hasConcept C71924100 @default.
• W2494173637 hasConcept C90924648 @default.
• W2494173637 hasConceptScore W2494173637C121608353 @default.
• W2494173637 hasConceptScore W2494173637C126322002 @default.
• W2494173637 hasConceptScore W2494173637C143998085 @default.
• W2494173637 hasConceptScore W2494173637C197934379 @default.
• W2494173637 hasConceptScore W2494173637C203092338 @default.
• W2494173637 hasConceptScore W2494173637C2777909004 @default.
• W2494173637 hasConceptScore W2494173637C2778260052 @default.
• W2494173637 hasConceptScore W2494173637C2779998722 @default.
• W2494173637 hasConceptScore W2494173637C2780456651 @default.
• W2494173637 hasConceptScore W2494173637C2780962732 @default.
• W2494173637 hasConceptScore W2494173637C2781187634 @default.

• next